Loss of tuberous sclerosis complex 2 (TSC2) is frequent in Hepatocellular carcinoma and predicts response to mTORC1 inhibitor everolimus

Molecular Cancer Therapeutics

Volumn 14, Issue 5, 2015, Pages 1224-1235

  Huynh, Hung ^a   Hao, Huai Xiang ^b   Chan, Stephen L ^c   Chen, David ^d   Ong, Richard ^a   Soo, Khee Chee ^a   Pochanard, Panisa ^b   Yang, David ^b   Ruddy, David ^b   Liu, Manway ^b   Derti, Adnan ^b   Balak, Marissa N ^b   Palmer, Michael R ^b   Wang, Yan ^b   Lee, Benjamin H ^b   Sellami, Dalila ^d   Zhu, Andrew X ^e   Schlegel, Robert ^b   Huang, Alan ^b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b Translational and Experimental Medicine   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d NOVARTIS PHARMA AG   (Switzerland)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; SOMATOMEDIN C RECEPTOR; TUBERIN; ANTINEOPLASTIC AGENT; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA SEQUENCE; FEMALE; HUMAN; HUMAN CELL; IC50; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; GENETICS; HEPATITIS B; LIVER NEOPLASMS; MUTATION; TREATMENT OUTCOME; TUMOR CELL LINE; VIROLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EVEROLIMUS; HEPATITIS B; HUMANS; LIVER NEOPLASMS; MALE; MICE; MULTIPROTEIN COMPLEXES; MUTATION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84942133816     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0768     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer Stat 2008;58:71-96.
2. Nagasue N, Kohno H, Chang YC, Taniura H, Yamanoi A, Uchida M, et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 1993;217:375-84.
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
5. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253-62.
6. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807-26.
7. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314-9.
8. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/-mice. Proc Natl Acad Sci U S A 2001;98:10320-5.
9. Scott PH, Brunn GJ, Kohn AD, Roth RA, Lawrence JC Jr. Evidence of insulinstimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci U S A 1998;95:7772-7.
10. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001;294:1942-5.
11. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-83, 83 e1-11.
12. Wang L, Wang WL, Zhang Y, Guo SP, Zhang J, Li QL. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res 2007;37:389-96.
13. Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003;97:1929-40.
14. Menon S, Yecies JL, Zhang HH, Howell JJ, Nicholatos J, Harputlugil E, et al. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signaling 2012;5:ra24.
15. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014;312:57-67.
16. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008;412:179-90.
17. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
18. Huynh H, Soo KC, Chow PK, Panasci L, Tran E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res 2006;12:4306-14.
19. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, et al. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol 2010;52:79-87.
20. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8.
21. Huynh H, Chow PK, Tai WM, Choo SP, Chung AY, Ong HS, et al. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol 2012;56:595-601.
22. Huynh H, Chow KH, Soo KC, Toh HC, Choo SP, Foo KF, et al. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 2009;13:1371-80.
23. Law BK, Chytil A, Dumont N, Hamilton EG, Waltner-Law ME, Aakre ME, et al. Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol 2002;22:8184-98.
24. Jiang WG, Sampson J, Martin TA, Lee-Jones L, Watkins G, Douglas-Jones A, et al. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer 2005;41:1628-36.
25. Chakraborty S, Mohiyuddin SM, Gopinath KS, Kumar A. Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer 2008;8:163.
26. Matsumura S, Imoto I, Kozaki K, Matsui T, Muramatsu T, Furuta M, et al. Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor suppressor in hepatocellular carcinoma. Clin Cancer Res 2012;18:3541-51.
27. Hung CC, Su YN, Chien SC, Liou HH, Chen CC, Chen PC, et al. Molecular and clinical analyses of 84 patients with tuberous sclerosis complex. BMC Med Genet 2006;7:72.
28. Nellist M, Sancak O, Goedbloed MA, Rohe C, van Netten D, Mayer K, et al. Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex. Eur J Hum Genet 2005;13:59-68.
29. HuJ, Zacharek S, He YJ, Lee H, Shumway S, Duronio RJ, et al. WD40protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase. Genes Dev 2008;22:866-71.
30. Huang KT, Huang YH, Li P, He B, Chen ZK, Yu X, et al. Correlation between tuberous sclerosis complex 2 and glycogen synthase kinase 3 beta levels, and outcomes of patients with hepatocellular carcinoma treated by hepatectomy. Hepatol Res 2014;44:1142-50.
31. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010;30:35-51.
32. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002;4:648-57.
33. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005;121:179-93.
34. Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ, et al. ARD1stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Sci Signaling 2010;3:ra9.
35. Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, Ishikawa S, et al. Highresolution characterization of a hepatocellular carcinoma genome. Nat Genet 2011;43:464-9.
36. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338:221.
37. Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen YB, Cunha LF, et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res 2014;20:1955-64.
38. Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med 2014;371:1426-33.
39. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012;44:694-8.
40. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012;44:760-4.
41. Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 2013;23:1422-33.
42. Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 2012;44:1117-21.
43. TCGA. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-9.
44. Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RG, McConkey D, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-22.
45. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010;15:5-13.
46. Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA, et al. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med 2012;4:139ra84.